Cita APA

Rugo, H., Oliveira, M., Howell, S., Dalenc, F., & Cortes, J. (2024). Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

Citación estilo Chicago

Rugo, H.S., M. Oliveira, S.J Howell, F. Dalenc, y J. Cortes. Capivasertib and Fulvestrant for Patients With Hormone Receptor-positive Advanced Breast Cancer: Characterization, Time Course, and Management of Frequent Adverse Events From the Phase III CAPItello-291 Study. 2024.

Cita MLA

Rugo, H.S., et al. Capivasertib and Fulvestrant for Patients With Hormone Receptor-positive Advanced Breast Cancer: Characterization, Time Course, and Management of Frequent Adverse Events From the Phase III CAPItello-291 Study. 2024.